selected scholarly activity
-
conferences
- LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC).. Journal of Clinical Oncology. 2022
- Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126.. Journal of Clinical Oncology. 269-269. 2022
- Comparison of side effects at 2 years in the randomised PACE-B trial (SBRT vs standard radiotherapy). Radiotherapy and Oncology. S197-S197. 2021
- Rurality and neighborhood socioeconomic deprivation associated with patient-reported outcomes andsurvivalin men with prostate cancer in NRG RTOG 0415.. Cancer Research. 2021
- Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415. PLoS ONE. 2021
- Longitudinal predictive ability of mapping algorithms: Secondary analysis of NRG Oncology/RTOG 0415.. Journal of Clinical Oncology. 60-60. 2021
- Impact of Pelvic Intensity-modulated Radiotherapy (IMRT) on Lymph Node Coverage and Dose to Critical Organs, Compare to Three-Dimensional Conformal Radiation Therapy (3D-CRT), in Localized High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics. e250-e250. 2020
- Patient Reported Outcomes in NRG Oncology/RTOG 0938, a Randomized Phase II Study Evaluating 2 Ultrahypofractionated Regimens (UHR) for Prostate Cancer (CaP). International Journal of Radiation Oncology Biology Physics. S119-S120. 2020
- A methodological comparison of mapping algorithms to obtain health utilities derived using cross-sectional and longitudinal data: Secondary analysis of NRG/RTOG 0415. Journal of Clinical Oncology. 2020
- IMPACT OF PELVIC INTENSITY-MODULATED RADIOTHERAPY (IMRT) ON LYMPH NODE COVERAGE AND DOSE TO CRITICAL ORGANS, COMPARE TO THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY (3D-CRT), IN LOCALIZED HIGH-RISK PROSTATE CANCER. Radiotherapy and Oncology. S68-S68. 2019
- NRG Oncology/RTOG 0415, hypofractionation in patients with low-risk prostate cancer: are patient reported outcomes the practice change tipping point?. Quality of Life Research. 38-39. 2017
- Randomized Study of Quality of Life in Patients with High-Risk Prostate Cancer Undergoing Radiotherapy: Role of Pelvic Nodal IMRT. International Journal of Radiation Oncology Biology Physics. E211-E212. 2017
- Investigation Into the Feasibility of Having Uniform Compliance Dosimetric Criteria Across Radiation Therapy Treatment Modalities for NRG Oncology/RTOG 0938 by Using Machine Learning. International Journal of Radiation Oncology Biology Physics. E230-E231. 2016
- NRG Oncology/RTOG 0415, Phase 3 Noninferiority Study Comparing 2 Fractionation Schedules in Patients With Low-Risk Prostate Cancer: Prostate-Specific Quality of Life Results. International Journal of Radiation Oncology Biology Physics. S2-S3. 2016
- NRG Oncology RTOG 0415: A randomized phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer.. Journal of Clinical Oncology. 1-1. 2016
- Patient reported outcomes in NRG Oncology/RTOG 0938, evaluating two ultrahypofractionated regimens (UHR) for prostate cancer (CaP).. Journal of Clinical Oncology. 27-27. 2016
- NRG Oncology RTOG 0415: A Randomized Phase 3 Noninferiority Study Comparing 2 Fractionation Schedules in Patients With Low-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics. 3-4. 2016
- Patient-Reported Outcomes in NRG Oncology/RTOG 0938, a Randomized Phase 2 Study Evaluating 2 Ultrahypofractionated Regimens (UHRs) for Prostate Cancer. International Journal of Radiation Oncology Biology Physics. 2-2. 2016
- Global Radiation Oncology Elective in Teaching CanMEDS Competencies. International Journal of Radiation Oncology Biology Physics. E377-E377. 2015
- The role of PET-CT in treatment decision making for women with locally advanced cervical cancer.. Journal of Clinical Oncology. 5523-5523. 2015
- Cardiac Sparing With Breath-hold Technique: A Dosimetric Evaluation of Benefits in Different Patient Populations. International Journal of Radiation Oncology Biology Physics. S257-S257. 2012
- Identifying Risk Factors for Locoregional Recurrence Following Postmastectomy Radiation Therapy. International Journal of Radiation Oncology Biology Physics. S251-S251. 2012
- Positron emission tomography/computed tomography (PET/CT) for the diagnosis of recurrent cancer (PETREC): A multicenter, prospective cohort study.. Journal of Clinical Oncology. 2012
- Electronic Web-based Technology Significantly Improves Quality of Life (QOL) Data Collection: Analysis of RTOG 0828. International Journal of Radiation Oncology Biology Physics. S111-S111. 2011
- An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival.. Journal of Clinical Oncology. 2011
- DELTA: A Randomized Trial of Decongestive Lymphatic Therapy for Women with Lymphedema following Treatment for Breast Cancer. International Journal of Radiation Oncology Biology Physics. S53-S53. 2009
- LDR Prostate Brachytherapy: Dosimetric Evaluation of Stabilizing Needles and Seminal Vesicle Implants. International Journal of Radiation Oncology Biology Physics. S353-S353. 2009
- Influence of Gold Seed Implantation on Defining Target Volumes for Conformal Radiotherapy of Prostate Cancer. International Journal of Radiation Oncology Biology Physics. S322-S322. 2008
- 183 Can an In Vitro Assay Predict Radiation Sensitivity in Patients with Carcinoma of the Prostate?. Radiotherapy and Oncology. S53-S53. 2006
- 14 Randomized Trial Comparing Iridium Plus External-Beam Radiation Therapy with External-Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate. Radiotherapy and Oncology. S5-S5. 2005
- 201 Anatomical variables may determine the value of IMRT in intermediate risk prostate cancer: A dosimetric evaluation between IMRT and 3D-CRT PLANS. Radiotherapy and Oncology. S59-S59. 2005
- Po‐Poster ‐ 29: Radiation‐induced apoptosis of lymphocytes to predict late toxicity from radiotherapy. Medical Physics. 2415-2415. 2005
- A randomized trial comparing a combination of iridium implant and external beam radiation to external beam radiation alone for patients with locally advanced prostate cancer. International Journal of Radiation Oncology Biology Physics. S448-S448. 2004
- Arm lymphedema in breast cancer patients: Is it always related to treatment. International Journal of Radiation Oncology Biology Physics. S402-S402. 2004
- Clinical screening for lymphedema in breast cancer patients: Validation of Canadian guidelines.. Radiotherapy and Oncology. S42-S42. 2004
- Lymphedema in breast cancer patients screened during the first year of a randomized trial: Is treatment always the cause?. Radiotherapy and Oncology. S42-S42. 2004
- Local tumor control in women with carcinoma of the cervix treated with the addition of nitroimidazole agents to radiotherapy: A meta-analysis. Radiology. 599-599. 2002
-
journal articles
- Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.. New England Journal of Medicine. 391:1413-1425. 2024
- Patterns of failure with 18F-DCFPyL PSMA-PET/CT in the post-prostatectomy setting: A regional cohort analysis.. Journal of the Canadian Urological Association. 19. 2024
- Quality of Life in Patients Enrolled in a Randomized Clinical Trial Evaluating Hypofractionated Radiotherapy for Intermediate Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics. 120:s54-s55. 2024
- Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionation External Beam Radiotherapy (EBRT) Boost for Unfavorable Intermediate and High-Risk Prostate Cancer; Early Results of PBS: A Phase II Randomized Trial (NCT03380806). International Journal of Radiation Oncology Biology Physics. 120:s126-s127. 2024
- Erratum.. International Journal of Radiation Oncology Biology Physics. S0360-3016(24)03323-6. 2024
- 124 Phase II Randomized Trial of Optimal Recurrence-Directed Therapy (RDT) Without or with Androgen-Deprivation Therapy (ADT) in Radio-Recurrent Oligo-Metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC): The OCOG-Rational-PCS Trial. Radiotherapy and Oncology. 198:s54-s55. 2024
- 23 Stereotactic Body Versus Conventional Fractionation External Beam Radiotherapy (EBRT) Boost for High-Risk Prostate Cancer (HR-PC); Early Results of PBS: A Phase II Randomized Trial (NCT03380806). Radiotherapy and Oncology. 198:s13-s14. 2024
- Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer. Journal of Clinical Oncology. 42:2377-2381. 2024
- Evaluation of Volumetric Response Assessment From SABR for Renal Cell Carcinoma. International Journal of Radiation Oncology Biology Physics. 119:832-837. 2024
- Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial. The Lancet. 403:2405-2415. 2024
- Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. The Lancet. 403:2416-2425. 2024
- Disease control outcomes of stereotactic body radiation therapy or moderate hypo‐fractionation for prostate cancer: Real‐world experience at two Canadian centers. Prostate. 84:193-202. 2024
- Long-term results of radiation with or without anti-androgens (AAT) in patients receiving salvage prostate bed radiation therapy (sRT) post prostatectomy.. Journal of Clinical Oncology. 42:320-320. 2024
- Characterizing Hematological Changes Following Repeated Exposure to Non-Targeted Low-Dose Ionizing Radiation in Prostate Cancer Patients.. Dose-Response. 22:15593258241276120. 2024
- Evaluation of Volumetric Response Assessment from Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Carcinoma (RCC). International Journal of Radiation Oncology Biology Physics. 117:e434-e434. 2023
- Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial. International Journal of Radiation Oncology Biology Physics. 117:370-377. 2023
- Long-Term Follow-Up Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Non-Inferiority Study Comparing Two Fractionation Schedules in Patients with Favorable-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics. 117:S3-S4. 2023
- 114 Stereotactic Body Radiation Therapy (SBRT) and Hypo-Fractionated Radiation Therapy (HFRT) Outcomes for Low and Intermediate-Risk Prostate Cancer (PRCA): Experience at Two Ontario Centres. Radiotherapy and Oncology. 186:S53-S53. 2023
- 147 Evaluation of Volumetric Response Assessment from Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Carcinoma (RCC). Radiotherapy and Oncology. 186:S67-S67. 2023
- Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer. New England Journal of Medicine. 389:612-619. 2023
- Impact of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer. Journal of Clinical Oncology. 41:3909-3916. 2023
- Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. International Journal of Radiation Oncology Biology Physics. 116:770-778. 2023
- Neighborhood Deprivation and Rurality Associated With Patient-Reported Outcomes and Survival in Men With Prostate Cancer in NRG Oncology RTOG 0415. International Journal of Radiation Oncology Biology Physics. 116:39-49. 2023
- Biochemical disease control outcomes of stereotactic body radiation therapy (SBRT) or moderate hypo-fractionation (HFRT) for low- and intermediate-risk prostate cancer (PrCa): Retrospective analysis of 12 years of experience at two Canadian cancer centers.. Journal of Clinical Oncology. 41:363-363. 2023
- Patterns of failure after radiotherapy (RT) in patients with prostate cancer re-staged with 18F-DCFPyL PSMA-PET: A regional cohort analysis.. Journal of Clinical Oncology. 41:45-45. 2023
- Patterns of failure with 18F-DCFPyL PSMA PET/CT in the post-prostatectomy setting: A regional cohort analysis.. Journal of Clinical Oncology. 41:309-309. 2023
- Low-Dose Hemibody Radiation, a Treatment Option for Recurrent Prostate Cancer: A Phase 2 Single-Arm Trial. Advances in Radiation Oncology. 8:101066-101066. 2023
- Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. The Lancet Oncology. 23:1308-1320. 2022
-
Salvage radiotherapy following
HiFU : An institutional series and literature review. Journal of Medical Imaging and Radiation Oncology. 66:847-852. 2022 - LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC).. Journal of Clinical Oncology. 40:LBA501-LBA501. 2022
- A systematic review of axillary nodal irradiation for the management of the axilla in patients with early-stage breast cancer. Surgical Oncology. 42:101754-101754. 2022
- Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415. JCO clinical cancer informatics. 6:e2100188. 2022
- The Journey of Radiotherapy Dose Escalation in High Risk Prostate Cancer; Conventional Dose Escalation to Stereotactic Body Radiotherapy (SBRT) Boost Treatments. Clinical Genitourinary Cancer. 20:e25-e38. 2022
- 151: Prostate SBRT Boost Radiotherapy (PBS Trial): A Randomized Phase II Trial of SBRT Versus Conventionally-Fractionated Radiotherapy Boost Following Pelvic Radiotherapy in High-Risk Prostate Cancer. Radiotherapy and Oncology. 163:S64-S64. 2021
- Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. Journal of Clinical Oncology. 39:3056-3082. 2021
- Abstract 2528: Rurality and neighborhood socioeconomic deprivation associated with patient-reported outcomes andsurvivalin men with prostate cancer in NRG RTOG 0415. Cancer Research. 81:2528-2528. 2021
- Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415. PLoS ONE. 16:e0249123-e0249123. 2021
- A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806). Clinical Genitourinary Cancer. 18:e410-e415. 2020
- Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer. Journal of the Canadian Urological Association. 14:123-130. 2020
- A methodological comparison of mapping algorithms to obtain health utilities derived using cross-sectional and longitudinal data: Secondary analysis of NRG/RTOG 0415.. Journal of Clinical Oncology. 38:55-55. 2020
- Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases. Asian Journal of Andrology. 22:437-437. 2020
- External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. The Lancet. 394:2165-2172. 2019
- Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. The Lancet Oncology. 20:1531-1543. 2019
- 158 Impact of Pelvic Intensity-Modulated Radiotherapy (IMRT) on Lymph Node Coverage and Dose to Critical Organs, Compare to Three-Dimensional Conformal Radiation Therapy (3D-CRT), in Localized High-Risk Prostate Cancer. Radiotherapy and Oncology. 139:S68-S68. 2019
- Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415. Radiotherapy and Oncology. 135:19-24. 2019
- Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy. JAMA Oncology. 5:664-664. 2019
- Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. International Journal of Radiation Oncology Biology Physics. 102:287-295. 2018
- Effect of Positron Emission Tomography Imaging in Women With Locally Advanced Cervical Cancer. JAMA network open. 1:e182081-e182081. 2018
- Long-Term Results of a Randomized Trial Comparing Iridium Implant Plus External Beam Radiation Therapy With External Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate. International Journal of Radiation Oncology Biology Physics. 99:90-93. 2017
- Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. Journal of Clinical Oncology. 35:1884-1890. 2017
- Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. Journal of Clinical Oncology. 34:2325-2332. 2016
- The Technique, Resources and Costs of Stereotactic Body Radiotherapy of Prostate Cancer. Technology in Cancer Research and Treatment. 15:171-178. 2016
- Biological Response of Positron Emission Tomography Scan Exposure and Adaptive Response in Humans. Dose-Response. 13:155932581561190-155932581561190. 2015
- 18F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer. British Journal of Cancer. 112:1737-1743. 2015
- Locoregional Therapy of Locally Advanced Breast Cancer: A Clinical Practice Guideline. Current Oncology. 22:54-66. 2015
- Long-term Survival in a Patient with Metastatic Spinal Cord Compression from a Prostate Cancer with Ultra-high PSA: Case Report and Review of the Literature. Cureus. 7:e242. 2015
- Can electronic web-based technology improve quality of life data collection? Analysis of Radiation Therapy Oncology Group 0828. Practical Radiation Oncology. 4:187-191. 2014
- Randomized Trial of Decongestive Lymphatic Therapy for the Treatment of Lymphedema in Women With Breast Cancer. Journal of Clinical Oncology. 31:3758-3763. 2013
- Systematic review: conservative treatments for secondary lymphedema. BMC Cancer. 12:6. 2012
- Intensity-modulated Radiotherapy in the Treatment of Breast Cancer. Clinical Oncology. 24:488-498. 2012
- Positron emission tomography/computed tomography (PET/CT) for the diagnosis of recurrent cancer (PETREC): A multicenter, prospective cohort study.. Journal of Clinical Oncology. 30:6049-6049. 2012
- Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways. Radiation Oncology. 6:144. 2011
- An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival.. Journal of Clinical Oncology. 29:7018-7018. 2011
- Conservative and dietary interventions for cancer‐related lymphedema. Cancer. 117:1136-1148. 2011
- In Reply to Dr. Azria et al.. International Journal of Radiation Oncology Biology Physics. 75:1275-1276. 2009
- Radiation-Induced Lymphocyte Apoptosis to Predict Radiation Therapy Late Toxicity in Prostate Cancer Patients. International Journal of Radiation Oncology Biology Physics. 74:1424-1430. 2009
- Lymphedema in women with breast cancer: characteristics of patients screened for a randomized trial. Breast Cancer Research and Treatment. 110:337-342. 2008
- Individual Radiosensitivity and its Relevance to Health Physics. Dose-Response. 5:dose-response.0. 2007
- Current issues in the management of lymphedema in breast cancer patients.. The Journal of Supportive Oncology. 4:392-393. 2006
- Cross-Border Referral for Early Breast Cancer: An Analysis of Radiation Fractionation Patterns. Current Oncology. 13:124-129. 2006
- The Importance of Reporting Patient Recruitment Details in Phase III Trials. Journal of Clinical Oncology. 24:843-845. 2006
- 59 Radiation — Induced apoptosis of lymphocytes to predict normal tissue late toxicity from radiotherapy. Radiotherapy and Oncology. 76:S18-S18. 2005
- Local tumour control in women with carcinoma of the cervix treated with the addition of nitroimidazole agents to radiotherapy: a meta-analysis. British Journal of Radiology. 78:777-782. 2005
- Randomized Trial Comparing Iridium Implant Plus External-Beam Radiation Therapy With External-Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate. Journal of Clinical Oncology. 23:1192-1199. 2005
- A randomized trial comparing a combination of iridium implant and external beam radiation to external beam radiation alone for patients with locally advanced prostate cancer. International Journal of Radiation Oncology Biology Physics. 60:S448-S448. 2004
- Arm lymphedema in breast cancer patients: Is it always related to treatment. International Journal of Radiation Oncology Biology Physics. 60:S402-S402. 2004
- BASELINE STAGING OF NEWLY DIAGNOSED PROSTATE CANCER: A SUMMARY OF THE LITERATURE. Investigative Urology. 171:2122-2127. 2004
- Unforeseen complication of brachytherapy. CANADIAN MEDICAL ASSOCIATION JOURNAL. 170:1209-1210. 2004
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting. Current Oncology. 31:6536-6567.